Role of palivizumab in prophylaxis of bronchiolitis caused by respiratory syncytial virus
Keywords:
Syncytial virus of the lungs, Palivizumab, Preterm, CytokinesAbstract
Infections with respiratory syncytial virus (RSV) are common. the most common causes of life-threatening respiratory illnesses medical treatment in the form of intensive care in some circumstances. Once .Resolved, there may be variable respiratory consequences severity.
Downloads
References
Anderson LJ, Barney S. Graham Editors Challenges and Opportunities for Respiratory Syncytial Virus Vaccines. Berlin Heidelberg: Springer-Verlag; 2013.
Collins PL, Melero J. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus rev. 2011;62:80–99.
Mastrangelo P, Hegele RG. Host and viral factors in respiratory syncytial virus infection. Curr Pediatr Rep. 2013;1:149–57.
Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360:588–98.
Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375:1545–55.
Medici MC, Arcangeletti MC, Rossi GA, Lanari M, Merolla R, Paparatti UD, et al. Four year incidence of respiratory syncytial virus infection in infants and young children referred to emergency departments for lower respiratory tract diseases in Italy: the “Osservatorio VRS” Study (2000–2004). New Microbiol. 2006;9:35–43.
Ralston SL, Lieberthal AS, Meissner HC, Alverson BK, Baley JE, Gadomski AM, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014;134:e1474–502.
Zorc JJ, Hall CB. Brochiolitis: Recent evidence on diagnosis and management. Pediatrics. 2010;125:342–9.
Baraldi E, Lanari M, Manzoni P, Rossi GA, Vandini S, Rimini A, et al. Inter-society consensus document on treatment and prevention of bronchiolitis in newborns and infants. Ital J Pediatr. 2014;40:65. http://www.ijponline.net/content/40/1/65.
Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen TP. Nebulised hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database Syst Rev. 2013;7:CD006458. doi:10.1002/14651858.CD006458.
Everard ML, Hind D, Ugonna K, Freeman J, Bradburn M, Cooper CL, et al. SABRE: a multicentre randomised control trial of nebulised hypertonic saline in infants hospitalised with acute bronchiolitis. Thorax 2014;69:1105–12.
Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV) Lina Bollani1, Eugenio Baraldi2, Gaetano Chirico3, Andrea Dotta4, Marcello Lanari5, Antonello Del Vecchio6,Paolo Manzoni7, Antonio Boldrini8, Piermichele Paolillo9, Sandra Di Fabio10, Luigi Orfeo11, Mauro Stronati12, Costantino Romagnoli13,14
POLICY STATEMENTUpdated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Riskof Hospitalization for Respiratory Syncytial Virus Infection, Organizational Principles to Guide and Define the ChildHealth Care System and/or Improve the Health of all Children
Long term follow-up of Palivizumab administration in children born at 29–32 weeks of gestation Ronen Bar-Yosepha, Julie Haddadb, Monnera Hannaa, Irena Kesselc, Amir Kugelmanb,d, Fahed Hakima,d,e,1, Lea Bentura
Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection, ISSN: 2164-5515 (Print) 2164-554X (Online) Journal homepage: https://www.tandfonline.com/loi/khvi20
Respiratory syncytial virus: diagnosis, prevention and management Rachael Barr, Christopher A. Green, Charles J. Sande and Simon B. Drysdale, Ther Adv Infectious Dis 2019, Vol. 6: 1–9 DOI: 10.1177/ 2049936119865798
Palivizumab for the prevention of respiratory syncytial virus infection Alexander L. Rogovik MD PhD Bruce Carleton PharmD Alfonso Solimano MD Ran Goldman MD FRCPC
E.A. Simoes, Respiratory syncytial virus infection, Lancet 354 (1999) 847–852.
N. Sigurs, R. Bjarnason, F. Sigurbergsson, et al., Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7, Am. J. Respir. Crit. Care Med. 161 (2000) 1501–1507
N. Sigurs, R. Bjarnason, F. Sigurbergsson, et al., Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls, Pediatrics 95 (1995) 500–505
N. Sigurs, P.M. Gustafsson, R. Bjarnason, et al., Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13, Am. J. Respir. Crit. Care Med. 171 (2005) 137–141.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
